ADP RESULTS FROM CHRISTCHURCH -2011
The ASia Pacific Evaluation of Chest pain Trial (ASPECT) was an observational study of 3582 patients presenting with to the ED with acute chest pain. Christchurch Hospital contributed 1000 patients. 421 (11·8%) patients had 30 day MACE.
9.8% were classified low risk by the ASPECT ADP  Modified TIMI=0  No new ischaemic ECG changes  No elevation of any 0/2h biomarkers in a POC multimarker panel.
MACE occurred in 0·9% of low risk patients  Sensitivity 99·3% (95% CI 97·9-99·8)  NPV 99·1% (97·3-99·8)
ADP RESULTS FROM CHRISTCHURCH -2012
2h Accelerated Diagnostic protocol to Assess Patients with chest pain symptoms using contemporary Troponins as the Only biomarker (ADAPT) was a sub-study of ASPECT including 1975 patients. 
AIM
To evaluate the safety and effectiveness of adopting Clinical Guidance Frameworks for possible ACS across the New Zealand National Health system by evaluating their adoption in 7 diverse hospitals.
The hypothesis was that introducing the guidance frameworks would increase the proportion of patients safely discharged home within six hours of presentation to ED.
METHODS -DESIGN
The study design was a pragmatic stepped-wedge implementation trial of guidance frameworks with 6 months control (or pre-implementation) and at least 4 months intervention (or post implementation).
A stepped-wedge design involves sites beginning the study one after another. This means that later sites could benefit from lessons learnt from earlier sites on how to best manage the change of practice.
METHODS -SETTING
Sites (acute hospitals) were included if they were willing to participate and intended to implement a guidance framework incorporating an ADP by 1 September 2015.
This allowed at least four months post-implementation data to be collected from all sites by the end of the study.
Sites were not eligible if they had a pre-existing clinical pathway or ADP for suspected ACS.
There were no restrictions regarding cTn assay/ADP or clinical guidance framework.
METHODS -IMPLEMENTATION
Participating sites were presented with evidence regarding published ADPs including ADAPT, EDACS, HEART, NACPR, TRAPID-AMI and the Vancouver Chest pain rule, and then chose which ADP they would use.
Blood sampling for cTn was to be done on arrival and then at either 1, 2 or 3 hours after presentation
Pre-implementation, there were meetings involving primary investigator MT and representatives from each stakeholder group
Stakeholders then planned and facilitated implementation at each site.
Clinical and management leaders were identified within the local health system. These people remained in contact throughout the process. In one hospital there was a local independent change management process.
METHODS -DATA COLLECTION
The data collection process was pre-planned and developed before study commencement.
Participants were identified from electronic diagnostic laboratory records of all patients who had blood drawn in the ED for a troponin test.
Each laboratory record is linked to a patient's NHI.
Using the NHI, each hopitals Decision Support department could pull basic demographic data including age, gender and ethnicity as well as follow-up data on all readmission ICD10 codes. The national mortality dataset (Ministry of Health) was used to capture deaths within the 30 day follow-up time frame.
Additional data was collected on those discharged within 6 hours coded as having an adverse event by contacting the local hospital clinicians, GPs and/or patients.
METHODS -OUTCOMES
The primary outcome: Proportion "successfully" discharged home within 6h (no major adverse cardiac event (MACE) during the following 30 days). The proportion of study patients discharged within 6 hours increased in every hospital with an overall change from 8.3% to 18.4%.
RESULTS -ADVERSE EVENTS
In the control cohort, 5 out of 962 patients (0.52%) discharged within 6 hours had a MACE within 30 days (1 NSTEMI, 4 Deaths).
In the intervention cohort, 16 out of 3632 patients (0.44%) discharged within 6 hours had a MACE within 30 days (8 NSTEMI, 1 STEMI, 1 Ventricular Tachycardia, 1 Cardiac Arrest and 5 Deaths).
The sensitivity for 30-day MACE or mortality did not change with guidance framework implementation; p=0.28. 
RESULTS -EVENTS PRE-IMPLEMENTATION

CONCLUSION
This study demonstrated that a clinical framework incorporating accelerated diagnostic pathways for patients with suspected acute coronary syndromes can be safely implemented into multiple EDs across a country over a short time interval.
This indicates that national adoption of similar guidance frameworks would be possible in many countries.
After implementation at each site, a greater proportion of patients were discharged within 6 hours without compromising safety.
This released thousands of hours of time for medical staff and resources which could be used for other sick patients.
In addition, more rapid investigative process allows patients to be reassured earlier that they are not having a heart attack and to return at an earlier time point to their families and normal life activities including work.
LIMITATIONS
More ideal to prospectively recruit individual patients and collect electronic data on each individual patient, but the grant for the research was insufficient to allow for this type of study.
Hospitals do not automatically record which patients are being investigated for ACS, so we had to rely on serial troponin measurements to capture the population of interest
We had to rely on ICD10 coding to quantify clinical outcomes .
We were unable to identify admissions and deaths outside New Zealand.
